Video

Unmet Needs and Investigational Therapies in mCSPC

Author(s):

Jason Hafron, MD

Dr Jason Hafron concludes his discussion of mCSPC by highlighting the need to work towards a cure for the disease, and two major clinical trials investigating triplet treatment regimens.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Channing J. Paller, MD, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
Channing J. Paller, MD, answers a question during a Zoom video interview
Jaspreet S. Sandhu, MD, answers a question during a video interview
Related Content
Phase 2 trial launches of opaganib plus darolutamide in mCRPC
February 4th 2025

Phase 2 trial launches of opaganib plus darolutamide in mCRPC

Hannah Clarke
The primary end point is 12-month radiographic progression-free survival.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Study points to increasing incidence of advanced prostate cancer in California
February 4th 2025

Study points to increasing incidence of advanced prostate cancer in California

Hannah Clarke
The data also showed that mortality plateaued in recent years despite declining in years prior.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine
January 30th 2025

MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine

Hannah Clarke
“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers," says Ganesh S. Palapattu, MD, FACS.
Trial of immune therapy in mCRPC expands enrollment to VA medical center
January 28th 2025

Trial of immune therapy in mCRPC expands enrollment to VA medical center

Hannah Clarke
Overall, the open-label phase 1/2 study is assessing the safety and anti-tumor activity with INKmune across 3 dose levels.
© 2025 MJH Life Sciences

All rights reserved.